PEER-REVIEWED PUBLISHED MANUSCRIPTS  

1)    Rubens RP and Henney CS:  Studies on the mechanism of lymphocyte-mediated cytolysis.  The use of Concanavallin A to delineate a distinctive killer T cell subpopulation.  Journal of Immunology 118:  180-186, 1977.

2)    Otte A, Rubens RP et al. Intracranial 11C-eletriptan (Relpax) distribution in humans. European Journal of Nuclear Med and Molec Imaging, “Image of the Month”, 2003

3)    Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T: Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder.  Journal of Biologic Psychiatry 59:1052 – 1060, 2006.

4)    Krystal A, McCall V, Fava M, Rubens R, Wessel T, Caron J, et al; "Evaluation of Eszopiclone Discontinuation after Co-therapy with Fluoxetine for Insomnia with Co-existing Depression".  Journal of Clinical Sleep Medicine, 2007;3(1):48-55

5)    Soares C, Joffe H, Rubens R, Caron J, Roth T, Cohen L; “ESZOPICLONE IN PATIENTS WITH INSOMNIA DURING PERIMENOPAUSE AND EARLYPOSTMENOPAUSE: A RANDOMIZED, CONTROLLED TRIAL”; Obstetrics and Gynecology, 2006;108:1402–10

6)     Walsh J, Krystal A, Amato D, Rubens R, et al, “Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations”; SLEEP, 2007;30(8):957-966.

7)     Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Amato D, Krishnan R, Eszopiclone Co-Administered With Escitalopram in Patients with Generalized Anxiety Disorder and Co-morbid Insomnia; Archives of Psychiatry, 2008; 65(5):551-562.

8)    Julia Boyle, Leanne Trick, Sigurd Johnsen, James Roach and Robert Rubens, Next-day cognition, psychomotor function, and driving related skills following nighttime administration of eszopiclone; Human Psychopharmacol Clin Exp (2008) 

9)    T. Roth, J. Price,  D. Amato,  R. Rubens,  J. Roach,  T. Schnitzer  “The Effect of Eszopiclone in Patients with Rheumatoid Arthritis and Co-existing Insomnia:  A Pilot Study”; Prim Care Companion J Clin Psychiatry 2009;11(6): 292-301   

10)  Milton K. Erman MD; James Walsh Ph.D, Gary Zammit Ph.D., Robert Rubens MD, MBA; Kendyl Schaefer MSc; Thomas Wessel MD, Ph.D; David Amato Ph.D; Judy Caron Ph.D.  “A Polysomnographic Placebo-Controlled Evaluation of the Efficacy and Safety of Eszopiclone Relative to Placebo and Zolpidem in the Treatment of Primary Insomnia”; J Clin Sleep Med 2008;4(3):229-234.

11)  Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. SLEEP 2010; 33(2):225-234.

12)  Fabrizio Stocchi, Ann Hsu, Sarita Khanna, Aaron Ellenbogen, Andreas Mahler, Grace Liang, Ulrich Dillmann, Robert Rubens, Sherron Kell, and Suneel Gupta. Comparison of IPX066 with Carbidopa-Levodopa plus Entacapone in Advanced PD Patients (ASCEND-PD Trial); Parkinsonism Relat Disord, 20 (12), 1335-1340.

13)  Nausieda, P., Hsu, A., Elmer, L., Gil, R., Spiegel, J., Singer, C., Khanna, S., Rubens, R., Kell, S., Modi, N. B., Gupta, S. (2015) Conversion to IPX066 from standard levodopa formulations in advanced Parkinson’s disease: Experience in clinical trials. J Parkinson Dis, 5(4):837-45. doi: 10.3233/JPD-150622

14)  Tetrud, J., Nausieda, P., Kreitzman, D., Liang, G. S., Nieves, A., Duker, A. P. Hauser R. A., Farbman, E. S, Ellenbogen, A., Hsu, A., Kell, S., Khanna, S., Rubens, R., Gupta, S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson’s disease. J Neurol Sci, in press.

15)  LeWitt, P. A., Verhagen, Metman, L., Rubens, R., Khanna, S., Kell, S. Gupta, S. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.  Clinical Neuropharmacology 2018.  In press

16)  Morgan JC, Dhall R, Rubens R, Khanna S, Gupta S. Dosing patterns during conversion to IPX066, extended-release carbidopa-levodopa (ER CD-LD), in Parkinson’s disease with motor fluctuations. Parkinson’s Disease. In Press

17)  Modi NB, Mittur A, Rubens R, Khanna S, Gupta S. Single-dose pharmacokinetics and pharmacodynamics of IPX203 in patients with advanced Parkinson’s disease: a comparison with immediate-release carbidopa-levodopa and with extended-release carbidopa-levodopa capsules. Clin Neuropharm 2019;42: 4–8.

18) Nishit B. Modi, PhD, Aravind Mittur, PhD, Phillip Dinh, PhD, Robert Rubens, MD, MBA, and Suneel Gupta, PhD.Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations.Clin Neuropharm 2019;42: 149–156

19) Stephenson D., et al, Enabling efficient use of digital health technologies to support Parkinson's disease drug development through precompetitive collaboration;